MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
MARAVAI LIFESCIENCES HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
18.3%−53.7 pts over 5 years
Operating margin
-115.9%−158.1 pts over 5 years
Net margin
-70.4%−101.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -28.3% | -40.5% | -8.1% | – | |
| Gross profit | -68.6% | -63.8% | -30.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -48.6% | |
| Return on assets | – | – | -14.7% | |
| Current ratio | – | 2.54 | 6.60 | |
| Debt to equity | – | 6.04 | 1.37 | |
| Interest coverage | – | 3.9× | -8.0× | |
| Inventory turnover | – | – | 3.4× | |
| Capex to revenue | – | 8.9% | 7.1% | |
| Diluted shares | – | 29M | 144M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Maravai Lifesciences generated $1.10B from operations and spent $140.30M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.10B
Used
$140.30M
Capital expenditure$140.30M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-70.4%
×Asset turnover0.21×
×Equity multiplier3.31×
=Return on equity, FY2025-48.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -70.4% | 0.21× | 3.31× | -48.6% |
| FY2024 | -55.9% | 0.21× | 3.36× | -39.0% |
| FY2023 | -41.2% | 0.15× | 3.92× | -24.7% |
| FY2022 | 24.9% | 0.42× | 4.88× | 51.2% |
| FY2021 | 22.8% | 0.50× | 7.89× | 90.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$130.77M
- Cash generatingOperating cash flow above zero-$57.57M
- Return on assets improvedROA up on the prior year-9.7% → -13.0%
- Earnings backed by cashOperating cash flow above net income-$57.57M vs -$130.77M
- Less leverageLong-term debt to assets fell28.8% → 37.2%
- Better liquidityCurrent ratio rose7.53 → 6.60
- No dilutionShare count did not rise138M → 144M
- Gross margin improvedGross margin up on the prior year41.79% → 18.30%
- More efficientAsset turnover rose0.17 → 0.18